Approximately 70% of tumor samples in EC were previously reported to exhibit reduced m6A levels, primarily due to a loss-of-function METTL14 mutation at the R298P site and activation of the AKT pathway to enhance EC proliferation and tumorigenesis [43]. This evidence concerns the gene AKT1 and neoplasm.